Variables That Could Influence Healing Time in Patients with Diabetic Foot Osteomyelitis
Abstract
:1. Introduction
2. Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Lazaro-Martinez, J.L.; Tardaguila-Garcia, A.; Garcia-Klepzig, J.L. Diagnostic and therapeutic update on diabetic foot osteomyelitis. Endocrinol. Diabetes Nutr. 2017, 64, 100–108. [Google Scholar] [CrossRef] [PubMed]
- Lazaro Martinez, J.L.; Garcia Alvarez, Y.; Tardaguila-Garcia, A.; Garcia Morales, E. Optimal management of diabetic foot osteomyelitis: Challenges and solutions. Diabetes Metab. Syndr. Obes. 2019, 12, 947–959. [Google Scholar] [CrossRef] [Green Version]
- Tardaguila-Garcia, A.; Sanz-Corbalan, I.; Garcia-Alamino, J.M.; Ahluwalia, R.; Uccioli, L.; Lazaro-Martinez, J.L. Medical Versus Surgical Treatment for the Management of Diabetic Foot Osteomyelitis: A Systematic Review. J. Clin. Med. 2021, 10, 1237. [Google Scholar] [CrossRef]
- Tardaguila-Garcia, A.; Garcia-Alvarez, Y.; Garcia-Morales, E.; Lopez-Moral, M.; Sanz-Corbalan, I.; Lazaro-Martinez, J.L. Long-Term Complications after Surgical or Medical Treatment of Predominantly Forefoot Diabetic Foot Osteomyelitis: 1 Year Follow. J. Clin. Med. 2021, 10, 1943. [Google Scholar] [CrossRef] [PubMed]
- Tardaguila-Garcia, A.; Sanz-Corbalan, I.; Lopez-Moral, M.; Garcia-Madrid, M.; Garcia-Morales, E.; Lazaro-Martinez, J.L. Are Digital Arthroplasty and Arthrodesis Useful and Safe Surgical Techniques for the Management of Patients with Diabetic Foot? Adv. Skin Wound Care. 2022, 35, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Tardaguila-Garcia, A.; Garcia Alvarez, Y.; Garcia-Morales, E.; Alvaro-Afonso, F.J.; Sanz-Corbalan, I.; Lazaro-Martinez, J.L. Utility of Blood Parameters to Detect Complications during Long-Term Follow-Up in Patients with Diabetic Foot Osteomyelitis. J. Clin. Med. 2020, 9, 3768. [Google Scholar] [CrossRef] [PubMed]
- Tardaguila-Garcia, A.; Garcia-Alvarez, Y.; Sanz-Corbalan, I.; Lopez-Moral, M.; Molines-Barroso, R.J.; Lazaro-Martinez, J.L. Could X-ray Predict Long-term Complications in Patients with Diabetic Foot Osteomyelitis? Adv. Skin Wound Care 2022, 35, 1–5. [Google Scholar] [CrossRef]
- Aragon-Sanchez, J.; Lipsky, B.A.; Lazaro-Martinez, J.L. Diagnosing diabetic foot osteomyelitis: Is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients? Diabet Med. 2011, 28, 191–194. [Google Scholar] [CrossRef]
- Lipsky, B.A.; Senneville, É.; Abbas, Z.G.; Aragón-Sánchez, J.; Diggle, M.; Embil, J.M.; Kono, S.; Lavery, L.A.; Malone, M.; van Asten, S.A.; et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes/Metab. Res. Rev. 2020, 36 (Suppl. S1), e3280. [Google Scholar] [CrossRef] [Green Version]
- Tardaguila-Garcia, A.; Sanz-Corbalan, I.; Garcia-Morales, E.; Garcia-Alvarez, Y.; Molines-Barroso, R.J.; Lazaro-Martinez, J.L. Diagnostic Accuracy of Bone Culture Versus Biopsy in Diabetic Foot Osteomyelitis. Adv. Skin Wound Care 2021, 34, 204–208. [Google Scholar] [CrossRef]
- Hinchliffe, R.J.; Forsythe, R.O.; Apelqvist, J.; Boyko, E.J.; Fitridge, R.; Hong, J.P.; Katsanos, K.; Mills, J.L.; Nikol, S.; Reekers, J.; et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes/Metabolism Res. Rev. 2020, 36, e3276. [Google Scholar] [CrossRef] [PubMed]
- Kalani, M.; Brismar, K.; Fagrell, B.; Ostergren, J.; Jorneskog, G. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care 1999, 22, 147–151. [Google Scholar] [CrossRef] [PubMed]
- Norgren, L.; Hiatt, W.R.; Dormandy, J.A.; Nehler, M.R.; Harris, K.A.; Fowkes, F.G.R. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J. Vasc. Surg. 2007, 45, S5–S67. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schaper, N.C.; van Netten, J.J.; Apelqvist, J.; Bus, S.A.; Hinchliffe, R.J.; Lipsky, B.A.; IWGDF Editorial Board. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab. Res. Rev. 2020, 36 (Suppl. S1), e3266. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lipsky, B.A.; Berendt, A.R.; Cornia, P.B.; Pile, J.C.; Peters, E.J.; Armstrong, D.G.; Deery, H.G.; Embil, J.M.; Joseph, W.S.; Karchmer, A.W.; et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 2012, 54, e132–e173. [Google Scholar] [CrossRef] [Green Version]
- Lipsky, B.A. Treating diabetic foot osteomyelitis primarily with surgery or antibiotics: Have we answered the question? Diabetes Care 2014, 37, 593–595. [Google Scholar] [CrossRef] [Green Version]
- Aragon-Sanchez, J. Treatment of diabetic foot osteomyelitis: A surgical critique. Int. J. Low. Extremity Wounds 2010, 9, 37–59. [Google Scholar] [CrossRef]
- Tardaguila-Garcia, A.; Lazaro-Martinez, J.L.; Sanz-Corbalan, I.; Garcia-Alvarez, Y.; Alvaro-Afonso, F.J.; Garcia-Morales, E. Correlation between Empirical Antibiotic Therapy and Bone Culture Results in Patients with Osteomyelitis. Adv. Ski. Wound Care 2019, 32, 41–44. [Google Scholar] [CrossRef]
- Tone, A.; Nguyen, S.; Devemy, F.; Topolinski, H.; Valette, M.; Cazaubiel, M.; Fayard, A.; Beltrand, É.; Lemaire, C.; Senneville, É. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: A multicenter open-label controlled randomised study. Diabetes Care 2015, 38, 302–307. [Google Scholar] [CrossRef] [Green Version]
- van Netten, J.J.; Bus, S.A.; Apelqvist, J.; Lipsky, B.A.; Hinchliffe, R.J.; Game, F.; Rayman, G.; Lazzarini, P.A.; Forsythe, R.O.; Peters, E.J.; et al. Definitions and criteria for diabetic foot disease. Diabetes/Metabolism Res. Rev. 2020, 36, e3268. [Google Scholar] [CrossRef]
- Rayman, G.; Vas, P.; Dhatariya, K.; Driver, V.; Hartemann, A.; Londahl, M.; Piaggesi, A.; Apelqvist, J.; Attinger, C.; Game, F.; et al. Guidelines on use of interventions to enhance healing of chronic foot ulcers in diabetes (IWGDF 2019 update). Diabetes/Metabolism Res. Rev. 2020, 36, e3283. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- General Assembly of the World Medical, A. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. J. Am. Coll. Dent. 2014, 81, 14–18. [Google Scholar]
- Tardaguila-Garcia, A.; Garcia-Alvarez, Y.; Sanz-Corbalan, I.; Alvaro-Afonso, F.J.; Molines-Barroso, R.J.; Lazaro-Martinez, J.L. Role of inflammatory markers in the healing time of diabetic foot osteomyelitis treated by surgery or antibiotics. J. Wound Care 2020, 29, 5–10. [Google Scholar] [CrossRef] [PubMed]
- van Asten, S.A.; Jupiter, D.C.; Mithani, M.; La Fontaine, J.; Davis, K.E.; Lavery, L.A. Erythrocyte sedimentation rate and C-reactive protein to monitor treatment outcomes in diabetic foot osteomyelitis. Int. Wound J. 2017, 14, 142–148. [Google Scholar] [CrossRef]
- Lazaro-Martinez, J.L.; Aragon-Sanchez, J.; Garcia-Morales, E. Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: A randomized comparative trial. Diabetes Care 2014, 37, 789–795. [Google Scholar] [CrossRef] [PubMed]
Variables | n = 116 |
---|---|
Male/female, n (%) | 96 (82.2)/20 (17.2) |
Age (years), mean ± SD | 62.9 ± 10.1 |
DM (years), mean ± SD | 17.5 ± 12.3 |
DM type 1/type 2, n (%) | 12 (10.3)/104 (89.7) |
Body mass index (Kg/m2), mean ± SD | 28.3 ± 5.5 |
HbA1c (%), mean ± SD | 8.1 ± 6.0 |
Neuropathy, n (%) | 116 (100.0) |
Affected superficial sensitivity, n (%) | 116 (100.0) |
Affected deep sensitivity, n (%) | 116 (100.0) |
PAD, n (%) | 48 (41.4) |
ABI; mean ± SD | 1.0 ± 0.3 |
TBI; mean ± SD | 0.7 ± 0.2 |
TcPO2; mean ± SD | 34.1 ± 13.9 |
Duration from ulcer (weeks), mean ± SD | 15.7 ± 32.1 |
Location of ulcer: forefoot/midfoot/hindfoot, n (%) | 107 (92.2)/5 (4.3)/4 (3.4) |
Presence of clinical signs of infection, n (%) | 72 (62.1) |
Radiological signs in X-ray: focal loss of trabecular pattern or marrow radiolucency (demineralisation)/periosteal reaction or elevation/sequestrum/loss of bone cortex, with bony erosion or demineralisation/another type of signs, n (%) | 34 (29.3)/36 (31)/12 (10.3)/26 (22.4)/8 (7) |
Blood parameters: leukocytes (×109/L)/neutrophils (×109/L)/lymphocytes (×109/L)/monocytes (×109/L)/eosinophils (×109/L)/basophils (×109/L)/ESR (mm/h)/glycaemia (mmol/L)/CRP) (nmol/L)/alkaline phosphatase (UI/L)/albumin (g/L)/creatinine (mg/dl), mean ± SD | 8.7 ± 2.5/5.6 ± 2.3/2.1 ± 0.9/0.7 ± 0.5/0.3 ± 0.2/0.04 ± 0.04/34.3 ± 28.4/8.45 ± 3.16/99.6 ± 46.5/40 ± 6/1.6 ± 1.7 |
Surgical treatment/medical treatment | 96 (82.2)/20 (17.2) |
Variables | Mean (weeks) | IQR (weeks) | p-Value |
---|---|---|---|
Elevated leukocytes | 13 | 9–21 | 0.761 |
Normalised leukocytes | 13 | 8–22 | |
Elevated neutrophils | 18 | 12–22 | 0.117 |
Normalised neutrophils | 12 | 8–20 | |
Elevated lymphocytes | 8 | 7.5–8.5 | 0.057 |
Normalised lymphocytes | 13 | 8–22 | |
Elevated monocytes | 12 | 6–20 | 0.557 |
Normalised monocytes | 13 | 8–22 | |
Elevated eosinophils | 35 | 23–35 | 0.004 |
Normalised eosinophils | 13 | 8–20 | |
Elevated ESR | 13 | 9–21 | 0.378 |
Normalised ESR | 12 | 8–22 | |
Elevated glycaemia | 12 | 8–22 | 0.831 |
Normalised glycaemia | 14 | 8.5–20 | |
Elevated HbA1c | 13 | 8–22 | 0.716 |
Normalised HbA1c | 16 | 8–20 | |
Elevated CRP | 13 | 8–22 | 0.278 |
Normalised CRP | 12 | 8–20 | |
Elevated alkaline phosphatase | 19 | 12–23 | 0.096 |
Normalised alkaline phosphatase | 13 | 8–20 | |
Elevated albumin | 11 | 10–12 | 0.634 |
Normalised albumin | 13 | 8–22 | |
Elevated creatinine | 12 | 8–23.5 | 0.972 |
Normalised creatinine | 13 | 8.5–20 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tardáguila-García, A.; Álvaro-Afonso, F.J.; García-Madrid, M.; López-Moral, M.; Sanz-Corbalán, I.; Lázaro-Martínez, J.L. Variables That Could Influence Healing Time in Patients with Diabetic Foot Osteomyelitis. J. Clin. Med. 2023, 12, 345. https://doi.org/10.3390/jcm12010345
Tardáguila-García A, Álvaro-Afonso FJ, García-Madrid M, López-Moral M, Sanz-Corbalán I, Lázaro-Martínez JL. Variables That Could Influence Healing Time in Patients with Diabetic Foot Osteomyelitis. Journal of Clinical Medicine. 2023; 12(1):345. https://doi.org/10.3390/jcm12010345
Chicago/Turabian StyleTardáguila-García, Aroa, Francisco Javier Álvaro-Afonso, Marta García-Madrid, Mateo López-Moral, Irene Sanz-Corbalán, and José Luis Lázaro-Martínez. 2023. "Variables That Could Influence Healing Time in Patients with Diabetic Foot Osteomyelitis" Journal of Clinical Medicine 12, no. 1: 345. https://doi.org/10.3390/jcm12010345
APA StyleTardáguila-García, A., Álvaro-Afonso, F. J., García-Madrid, M., López-Moral, M., Sanz-Corbalán, I., & Lázaro-Martínez, J. L. (2023). Variables That Could Influence Healing Time in Patients with Diabetic Foot Osteomyelitis. Journal of Clinical Medicine, 12(1), 345. https://doi.org/10.3390/jcm12010345